脂肪酸侧链 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
== Principle of chemical ligation == The "chemical ligation" concept was introduced by Kent in the early 1990s. It consisted of a novel approach to the covalent condensation of unprotected peptide segments by means of "unique, mutually reactive functionalities, one on each reacting peptide segment, designed to react only with each other and not with any of the functional groups found in (native) peptides". Chemical ligation of unprotected peptides is enabled by formation of an unnatural moiety, i.e. non-peptide bond, linking the two peptide segments in the ligation product. It was envisioned as a general method that would greatly simplify the chemical synthesis of protein molecules and enable the application of the entire repertoire of chemistry to the world of the proteins.
The capsules were included in Grazia magazine's Top 10 "Best Collagen Supplements. In May 2022, fashion retailer New Look posted a short clip on social media of a blonde woman walking down a corridor, with the caption "Our New Look family just gained a new member! Can you guess who it is?". Two days later, it was revealed to be Collins, who signed a deal worth over £1 million to collaborate with the company on a range of clothing. The exclusive collection designed by Collins herself, included bikinis, tops, dresses and jumpsuits available in sizes 8 to 28 that were inspired by "glamorous locations around the world" and also featured a range of jewellery, shoes and accessories. The collection launched online on 16 May, with Collins hosting a launch party in London that evening. It became available in stores three days later and Collins visited the Liverpool One branch where she held auditions for the public to show off their "modelling moves" in hope of being part of the company's autumn/winter campaign. Following her collaboration with the company, Collins made the decision to close down her clothing boutique after nine years, and at the time of its closure, was the longest-standing of her The Only Way Is Essex co-stars businesses. In June 2022, she collaborated with the hair care brand Aussie to promote their "Deeep Moisture" range. Collins, a consumer of the product herself said that the conditioner had "come to the rescue" after her previous desire to be the "blondest person on the earth" had left her with "dry, damaged locks".
Autologen, an injectable dermal material made from the patient's own skin. No risk of allergy exists but the results are very temporary because the body quickly absorbs the material. Collagen requires an allergy test because the material is extracted from bovine hides. It lasts anywhere from four weeks to three months because it is also absorbed into the body. However, the allergy test must be observed for four weeks. Dermalogen is taken from the patient's skin—and through a laboratory process—made into a high concentration collagen that can be injected into the lips. Some studies indicate it lasts somewhat longer than collagen. Alloderm is donor tissue taken from cadavers and then denatured, purified and treated to remove viable cells that could pass along disease. Under a local anesthesia, Alloderm is placed into the mucosa, or body, of the lips in small rolls to make them larger. Alloderm can also be placed into the vermilion, the pink area of the lip, to provide definition and a sharper border. Radiance, a synthetic, laboratory produced solution containing calcium hydroxylapatite (bone) suspended in a gel that has been safely used in medicine for years. Some studies indicate Radiance can last between three and five years. One researcher (Tzikas) found in a study of Radiance on 90 patients that 59 percent felt when injected, moderate to severe pain which disappeared two to five minutes later. But the substance produced results for an average of two years with a few patients reporting the plumping effects being sustained as long as three to five years.
Sources: en.wikipedia.org
In molecular biology, protein catabolism is the breakdown of proteins into smaller peptides and ultimately into amino acids. Protein catabolism is a key function of the digestion process. Protein catabolism often begins with pepsin, which converts proteins into polypeptides. These polypeptides are then further degraded. In humans, the pancreatic proteases include trypsin, chymotrypsin, and other enzymes. In the intestine, the small peptides are broken down into amino acids that can be absorbed into the bloodstream. These absorbed amino acids can then undergo amino acid catabolism, where they are utilized as an energy source or as precursors to new proteins. The amino acids produced by catabolism may be directly recycled to form new proteins, converted into different amino acids, or can undergo amino acid catabolism to be converted to other compounds via the Krebs cycle.
On 7 April, Trump announced that the US and Iran had reached an agreement based on the 10-point proposal mediated by Pakistani prime minister Shehbaz Sharif and Field Marshal Asim Munir. The US, Israel, and Iran agreed to a two-week ceasefire, under which Iran would re-open the Strait of Hormuz. After the announcement, Iran's Lavan Island oil refinery and Sirri Island crude export facilities were struck; no party claimed responsibility. In response, Iran continued missile and drone strikes on Gulf Arab states. The refinery attack was later revealed to have been done secretly by the UAE.
Oriented strand board is manufactured in wide mats from cross-oriented layers of thin, rectangular wooden strips compressed and bonded together with wax and synthetic resin adhesives. The adhesive resins types used include: urea-formaldehyde (OSB type 1, nonstructural, nonwaterproof); isocyanate-based glue (or PMDI poly-methylene diphenyl diisocyanate–based) in inner regions with melamine-urea-formaldehyde or phenol formaldehyde resin glues at surface (OSB type 2, structural, water resistant on face); phenol formaldehyde resin throughout (OSB types 3 and 4, structural, for use in damp and outside environments). The layers are created by shredding the wood into strips, which are sifted and then oriented on a belt or wire-mesh caul (a heated, ventilated support) and coated with the resin. The layers thus built up are transferred to a forming line and cross-oriented so that strips on the external layers are aligned to the panel's strength axis, while the internal layers are perpendicular. The number of layers placed is determined partly by the thickness of the panel, and is limited by the equipment used. Individual layers can also vary in thickness to give different finished panel thicknesses; typically, a 15 cm (5.9 in) layer will produce a 15 mm (0.59 in) panel thickness. The mat is placed in a thermal press to compress the flakes and bond them by heat activation and curing of the resin. Individual panels are then cut from the mats into finished sizes. Most of the world's OSB is made in the United States and Canada in large production facilities.
=== Sulfuric acid production === Up to the 1970s, commercial quantities of sulfuric acid were produced from anhydrous calcium sulfate. Upon being mixed with shale or marl, and roasted at 1400°C, the sulfate liberates sulfur dioxide gas, a precursor to sulfuric acid. The reaction also produces calcium silicate, used in cement clinker production.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.